2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 90

Developing a Pediatric Rheumatology Curriculum for Pediatric Residents
Abstract Number: 2047

Development and Implementation of a “Data-in-Once” Model for a Pediatric Rheumatology Learning Health System
Abstract Number: 918

Development and Validation of a Clinical Rule to Facilitate Recognition of Clinical Arthritis By General Practitioners
Abstract Number: 246

Development and Validation of a Flourescence Optical Imaging Rheumatoid Arthritis Scoring System for Synovitis in the Wrist and Hand
Abstract Number: 1839

Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials
Abstract Number: 1489

Development and Validation of a Questionnaire to Assess Healthcare Utilization and Access in Cohorts of Patients with Primary Sjögren’s Syndrome
Abstract Number: 2046

Development and Validation of a Rheumatologist Satisfaction with Practice Scale –“ the Rheumatologist Satisfaction Scale” (RSS)
Abstract Number: 1946

Development of a Multi-Component 3D Arthritic Joint Model
Abstract Number: 695

Development of a Multimarker Model for the Detection of Systemic Lupus Erythematosus Based on New and Traditional Autoantibodies
Abstract Number: 1449

Development of a Predictive Score of Successful TNF Inhibitor Tapering in Patients with Rheumatoid Arthritis Remission
Abstract Number: 2659

Development of a Protocol for Single Cell Transcriptomics of Cells from Cryopreserved Lupus Nephritis Kidney Tissue and Urine for the Accelerating Medicines Partnership RA/SLE Network
Abstract Number: 1818

Development of Abatacept- and Adalimumab-Specific Predictive Models of Response to Therapy in RA Using Data from a Head-to-Head Study
Abstract Number: 1371

Development of an Adjusted Multi-Biomarker Disease Activity (MBDA) Score for Rheumatoid Arthritis (RA) That Accounts for Age, Sex and Adiposity, with Subsequent Evaluation of Ability to Predict Risk for Radiographic Damage
Abstract Number: 1874

Development of an Ultrasonographic Enthesitis Score for Psoriatic Arthritis Patients
Abstract Number: 1837

Development of Murine SLE in the Absence of BAFF

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].